Navigation Links
Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
Date:11/6/2009

RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, presented updates on the development of the company's lead antiviral compound, CMX001, to the World Health Organization (WHO) and the Global Health Security Initiative (GHSI). CMX001 is a broad-spectrum antiviral agent being developed for the treatment of smallpox, as well as other serious viral infections.

Randall Lanier, Ph.D., Director of Virology for Chimerix, spoke at the WHO 11th meeting of the Advisory Committee on Variola Virus Research in Geneva, Switzerland, on Wednesday, November 4, 2009. George Painter, Ph.D., Chimerix's Chief Executive Officer, spoke to the GHSI's Public Health Emergency Medical Countermeasures Workshop on Thursday, November 5, 2009. Dr. Painter's and Dr. Lanier's presentations included updates on the development of CMX001 for both biodefense and commercial uses as a broad-spectrum antiviral against double-stranded DNA viruses, including variola, as well as recent uses of the product under Emergency Investigational New Drug (E-IND) protocols against adenovirus and progressive vaccinia in immune-compromised patients.

Dr. Painter said, with regard to both the WHO and GHSI presentations, "We are quite pleased with the progress of CMX001 and look forward to working with both the U.S. and international public health and transplant communities to continue to move the product toward regulatory approval."

CMX001 combines Chimerix's PIM (phospholipid intramembrane microfluidization) Conjugate Technology with cidofovir, an approved antiviral agent, with the aim of creating a well-tolerated and highly potent new chemical entity with broad-spectrum antiviral activity. CMX001 is initially being developed for both commercial and medical preparedness uses. Chimerix is currently conducting clinical trials of CMX001 for the treatment of cytomegalovirus (CMV) and BK virus in immunocompromised transplant patients. The company has also received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of CMX001 as a treatment in the event of a smallpox outbreak.

About the GHSI Meeting

This year's GHSI workshop was hosted by the United States Department of Health and Human Services, Assistant Secretary for Preparedness and Response (ASPR), and the Biomedical Advanced Research and Development Authority (BARDA) in Washington, DC. The GHSI consists of the Group of Seven nations, along with Mexico, and is charged with facilitating international cooperation for the development and procurement of medical countermeasures for both biodefense and global health. More information about the meeting may be found at http://www.blsmeetings.net/2009GHSImeetingsMCM/index.html

About Chimerix

Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being evaluated for use as a treatment in the event of a smallpox outbreak. Chimerix has received financing from leading venture capital firms, including Canaan Partners, Alta Partners, Sanderling Ventures, Frazier Healthcare Ventures and Asset Management Company, in addition to U.S. Government grants. Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.

SOURCE Chimerix, Inc.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
4. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
5. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
6. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
7. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
8. BioCryst Updates Peramivir Clinical Development Plan
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
11. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
Breaking Medicine News(10 mins):